Androski Lindsay reported tax withholding involving 82,527 shares of Arbutus Biopharma Corp at $5.07 for −$418k on Sep 18, 2026

Tax withholding
Form 4 code F. Payment of an exercise price or tax liability by delivering or withholding securities in a Rule 16b-3 transaction.
President and CEO
President and CEO
Filed Sep 23, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
−$418,411.89Shares × reported price
Shares traded
82,527Common Shares
Price per share
$5.07Reported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
72,337Direct
Trade date
Sep 18, 2026Tax withholding
Filed
Sep 23, 2026, 8:32 PM ET6-day reporting delay
Accession
0001447028-26-000053Code F · Transaction 228764
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
Sep 18, 2026Option exercise116,408$3.20$372,505.60Trade 228762
Sep 18, 2026Option exercise10,456$4.39$45,901.84Trade 228763
Sep 18, 2026Option exercise116,408$0.00$0Trade 228765
Sep 18, 2026Option exercise10,456$0.00$0Trade 228766
5 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
delayed filingThe filing was reported 6 calendar days after the transaction date.

ABUS price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
ABUS · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.

Return windows are pending. The first 7-day window is eligible on Oct 1, 2026. Values appear when the daily price refresh supplies a valid close for that window. Weekends, market holidays and missing prices can delay updates.

Pre-filing1mo ago1w ago1d ago
Returns since7d30d90d180d1y

Footnotes in full

F1: The Reporting Person exercised options on September 18, 2026. The Issuer withheld an aggregate of 82,527 shares otherwise issuable upon the exercises to satisfy the aggregate exercise prices. F2: The option, representing a right to purchase a total of 310,422 shares, vests over a four-year period, with 25% of the total shares subject to the option vesting on the 1st anniversary of the March 18, 2025 grant date and the remaining 75% vesting over the subsequent three-year period in substantially equal monthly installments at a rate of 1/48th of the total shares subject to the option each month, subject to the Reporting Person's continuous service as of each vesting date. F3: The option, representing a right to purchase a total of 71,700 shares, vests over a four-year period, with 1/48th of the shares subject to the option vesting in substantially equal monthly installments measured from one month following the February 2, 2026 grant date, subject to the Reporting Person's continuous service as of each vesting date.